@article{3aa3a567efd74a79b0a3bbf11b53eeaf,
title = "Hospitalisation Is Prognostic of Survival in Chronic Thromboembolic Pulmonary Hypertension",
author = "Pavel Jansa and David Ambro{\v z} and Michael Aschermann and Vladim{\'i}r {\v C}ern{\'y} and Vladim{\'i}r Dytrych and Samuel Heller and Jan Kunst{\'y}{\v r} and Jaroslav Lindner and Ale{\v s} Linhart and Mat{\'u}{\v s} Ni{\v z}nansk{\'y} and Michal Pa{\v d}our and Tom{\'a}{\v s} Prskavec and Michal {\v S}iranec and Susan Edwards and Virginie Gressin and Maty{\'a}{\v s} Kuhn and {Di Scala}, Lilla",
note = "Funding Information: Pavel Jansa has received fees and grants from Janssen Pharmaceutical Companies of Johnson and Johnson, AOP Orphan, Bayer Healthcare Pharmaceuticals, and MSD. Susan Edwards, Virginie Gressin, and Lilla Di Scala are employees of and have shares in Janssen, a pharmaceutical company of Johnson and Johnson. The remaining authors declare no conflicts of interest. Authors Susan Edwards, Virginie Gressin, and Lilla Di Scala (employees of study funders) had a role in the design of the study, analyses and interpretation of the data, in the writing and reviewing of the manuscript, and in the decision to publish the results. Funding Information: Medical writing support was provided by Victoria Atess and Clare Lowe, of Ashfield MedComms, an Inizio company, and funded by Actelion Pharmaceuticals Ltd., Allschwil, Switzerland, a Janssen Pharmaceutical company of Johnson and Johnson. Funding Information: This research was funded by Actelion Pharmaceuticals Ltd., Allschwil, Switzerland, a Janssen Pharmaceutical company of Johnson and Johnson. The APC and medical writing support were funded by Actelion Pharmaceuticals Ltd., Allschwil, Switzerland, a Janssen Pharmaceutical company of Johnson and Johnson. Publisher Copyright: {\textcopyright} 2022 by the authors.",
year = "2022",
month = oct,
doi = "10.3390/jcm11206189",
language = "English",
volume = "11",
journal = "Journal of Clinical Medicine",
issn = "2077-0383",
publisher = "MDPI AG",
number = "20",
}